Clinical Use Of Cb1 Antagonists Sr 141716

The selective CB1 antagonist SR 141716 (rimonabant or Acomplia; Sanofi-Synthelabo), when administered to marijuana smokers, caused weight loss in overweight and obese subjects without causing adverse side effects (118). Based on this and the promising studies on animals (reviewed previously), SR 141716 has been used in randomized, double-blind clinical trials to determine its efficacy in treating obesity and related metabolic complications. Several Phase III clinical trials named RIO (Rimonabant In Obesity) were initiated starting in 2001 and included more than 6600 overweight or obese patients with or without comorbidities who were given SR141716 (5 or 20 mg) or placebo for up to 2 yr (119 - 121). All subjects were on a calorie-restricted diet and underwent a run-in period of diet alone prior to being randomized to drug or placebo conditions.

Weight Loss Resolutions

Weight Loss Resolutions

Are You Tired Of Failed New Year's Weight Loss Resolutions That Leave You Even More Overweight Than Ever Before? Not Anymore Finally Succeed With Your New Years Weight Loss Resolution Once And For All And Get The Body Of Your Dreams.

Get My Free Ebook


Post a comment